English, Article edition: Drug Costs Developments after Patent Expiry of Enalapril, Fluoxetine and Ranitidine: A Study Conducted for the Netherlands Cornelis Boersma; Rogier M. Klok; Jasper M. Bos; ...

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/93165
Physical Description
  • article
Language
  • English

Edition details

Title
  • Drug Costs Developments after Patent Expiry of Enalapril, Fluoxetine and Ranitidine: A Study Conducted for the Netherlands
Author
  • Cornelis Boersma
  • Rogier M. Klok
  • Jasper M. Bos
  • Mark Naunton
  • Paul B. van den Berg
  • Lolkje T.W. de Jong-van den Berg
  • Maarten J. Postma
Physical Description
  • article
Notes
  • Background: In order to increase price competition, government regulations focus on controlling drug costs. Drug costs after patent expiry are an area of particular interest because the substitution of branded medication with generics represents an opportunity for lowering drug costs. However, drug costs may not decrease after patent expiry, because of a lack of price competition and different national pricing systems. Aim: The aim of this study was to investigate the trends in the use of generics after patent expiry for enalapril, fluoxetine and ranitidine and the subsequent changes, if any, in the costs of these medications. Methods: A drug-utilisation study was performed using data from a large sample of Dutch pharmacies. Both volumes (measured as defined daily doses [DDD] per 1000 population) as well as drug costs (calculated per DDD) prior to and after patent expiry were calculated. Costs per DDD were compared using trend-line analysis. In addition, the relative market shares of the different trade channels (branded, parallel imported and generic) were compared before and after patent expiry. Results: The costs per DDD decreased for all three drugs and, as expected, these costs decrease more rapidly after patent expiry. Significant differences in the trend lines were found for enalapril and fluoxetine. Conclusions: Despite relatively high reimbursement prices for generics in the Netherlands, this example from the Dutch pharmaceutical market demonstrates the benefit of generic substitution for containing pharmaceutical costs, which contrasts with concerns raised by the Dutch government.
  • Cost-analysis, Drug-utilisation, Enalapril, Fluoxetine, Generic-substitution, Ranitidine
  • RePEc:wkh:aheahp:v:4:y:2005:i:3:p:191-196
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment